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352Objective: Optimizing the multimodality treatment of malignant pleural mesothelioma depends on many factors
including an adequate chemotherapeutic response. Currently, chemotherapy regimens for patients with mesothe-
lioma are empirically selected. In vitro chemotherapy resistance in human mesothelioma has not been reported.
Our goal was to determine the prevalence of drug resistance in a large sample of malignant pleural mesothelioma
using a commercially available assay.
Methods: Tumors specimens (n ¼ 203) were cultured for analysis of chemoresistance using the extreme drug
resistance assay. Evaluable results were obtained in 168 (168/203¼ 83%) specimens. Each specimen was tested
with 3 drugs: cisplatin, gemcitabine, and vinorelbine. Drug resistance was characterized as low, intermediate, or
extreme. Median age was 64 years (30–85 years). Forty-four (26%) patients received neoadjuvant chemotherapy
before sampling and testing. The distribution of histopathologic cell types was epithelial (103; 61%), mixed (57;
34%), and sarcomatoid (8; 5%).
Results: A significant proportion of tumors had extreme/intermediate drug resistance to cisplatin (27%), gemci-
tabine (31%), or vinorelbine (59%). Nineteen tumors (11%) had extreme/intermediate resistance to all 3 drugs.
Resistance (extreme/intermediate) to cisplatin was more prevalent in epithelial tumors than in nonepithelial (33%
vs 18%; P ¼ .0394). No significant differences in chemoresistance were found in tumors of patients who had
received neoadjuvant chemotherapy compared with those who had not.
Conclusions: The feasibility of performing off-site in vitro drug resistance assays on resected malignant meso-
thelioma specimens is reported. A significant proportion of mesothelioma tumors exhibited extreme/intermediate
resistance to cisplatin, gemcitabine, or vinorelbine. (J Thorac Cardiovasc Surg 2010;140:352-5)Malignant pleural mesothelioma (MPM) is a rare and
aggressive cancer that is associated with a poor prognosis.
Despite improvements in overall median survival with the
multimodality approach,1,2 survival in MPM still lags
behind other thoracic malignancies, such as non–small cell
lung cancer.
Response rates of mesothelioma tumors to various single
chemotherapy agents consistently have been low,3 suggest-
ing the need for improved chemotherapy efficacy and/or
selection to optimize multimodality treatment. Although
combination chemotherapy has been associated with higher
response rates in patients with MPM, these response rates do
not necessarily translate into longer median survival.4
With current methods, the response of an individual tumor
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The Journal of Thoracic and Cardiovascular Surgcally, risking significant toxicity in patients who may not
respond to the treatment and losing precious time in a disease
associated with a short survival.5 Therefore, investigation of
new methods to assay individual tumor characteristics is
warranted.
Drug resistance profiles have been reported for various other
malignant diseases, including non&small cell lung cancer,
ovarian, breast, colon, esophageal cancer, and carcinoid.6-11
Some patients who have undergone chemoresistance assay–
directed treatment have had significantly longer disease-free
and overall survival duration.12
We report the results of a single-center experience with an
in vitro chemoresistance assay in a pathologically diverse
cohort of MPM tumors. We used a currently available com-
mercial assay to test for drug resistance to cisplatin, gemci-
tabine, and vinorelbine, 3 agents commonly used to treat
mesothelioma. To our knowledge, this is the first study to
characterize in vitro chemoresistance in MPM.METHODS
MPM Specimens
Fresh MPM specimens were obtained from patients undergoing surgery
at the Brigham and Women’s Hospital, placed in transport medium, and ex-
press shipped to Oncotech (now known as Exiqon Diagnostics) in Tustin,
California, for analysis by extreme drug resistance assay (EDR Assay;ery c August 2010
TABLE I. Patient characteristics
N (%) N (%)
Gender 139 male (83) 29 female (17)
Laterality 91 right (54) 77 left (46)
Neoadjuvant treatment 44 yes (26) 124 no (74)
Resectable* 146 yes (94) 10 no (6)
Histopathologic cell type 103 epithelial (61) 57 mixed (34)
8 sarcomatoid (5)
*This category applies only to the 156 patients who underwent definitive cytoreductive
surgery (extrapleural pneumonectomy or pleurectomy/decortication).
80
100
120
140
s
p
e
c
i
m
e
n
s
Drug Resistance Assay
Low
Abbreviations and Acronyms
EDR ¼ extreme drug resistance
IDR ¼ intermediate drug resistance
LDR ¼ low drug resistance
MPM ¼ malignant pleural mesothelioma
OR ¼ odds ratio
Mujoomdar et al General Thoracic Surgery
G
T
SOncotech/Exiqon, Vedbaek, Denmark).13 Specimens were assayed over
a 2-year period (2006–2008). We excluded from the study cohort cases
that were not primary MPM and specimens that demonstrated only partial
growth. We also excluded repeat assays from individuals with recurrent tu-
mors because it has been reported that recurrent lesions may exhibit greater
heterogeneity and more frequent EDR. In total, 203 MPM tumor samples
were obtained.
Tissue culture was successful in 168 (83%) of 203 resection specimens.
This evaluability rate was similar to previously reported rates for other dis-
eases.7
Patient Data
EDR assay results were entered into the clinical record for each patient
and then were obtained retrospectively along with demographic, pathologic,
and prior treatment data from the International Mesothelioma Program Pa-
tient Data Registry under an institutional review board–approved protocol.
Specimen Handling and in Vitro EDR Assay
The protocol for specimen handling has been previously published.13,14
In brief, viable tumor cells are cultured in soft-agarose medium at approxi-
mately 30,000 cells per well in 24-well plates, each with a single chemother-
apeutic agent (cisplatin, gemcitabine, or vinorelbine). After 72 hours of
incubation, tritiated thymidine is added to each well and left for an addi-
tional 48 hours. Tumor cell DNA is harvested and tritium incorporation is
measured on a scintillation counter as an indicator of cellular proliferation.
Positive controls (supralethal exposure to cisplatin, gemcitabine, and vinor-
elbine) and negative controls (exposure to media only) are performed with
each assay. The results are reported as in vitro cell proliferation, relative to
the median of a historical database of over 100,000 human tumors of varied
histologic types submitted for EDR assay. This measure is corrected using
the negative and positive controls.
Specimens are considered to have EDR when the in vitro cellular prolif-
eration rate is greater than 1 SD above the median. This indicates that tumor
cell growth in the specimen has been virtually unaffected by exposure to the
cytotoxic agent. Intermediate drug resistance (IDR) indicates moderate
tumor growth (in vitro cell proliferation is greater than the median but
less than 1 SD above the median). Low drug resistance (LDR) indicates
that tumor cell proliferation was inhibited by the tested agent (in vitro cell
proliferation is less than the median).
Statistical Analysis
Statistical analysis and data collection were performed pursuant to an
institutional review board–approved protocol. Patient tumor cultures were
tested against a panel of 3 individual drugs. Statistical analysis was done
using a 2-way c2 test. We are reporting the exact P values.0
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FIGURE 1. Drug resistance assay results among malignant pleural meso-
thelioma tumors.RESULTS
The characteristics of the study population are summa-
rized in Table 1. A significant proportion of MPM tumors
had IDR or EDR to cisplatin (27%), gemcitabine (31%),The Journal of Thoracic and Caor vinorelbine (59%) (Figure 1). Fifteen (88%) of 17 tumors
with EDR to cisplatin also had EDR to either gemcitabine
(n¼ 10) or vinorelbine (n¼ 9). Four (24%) of the 17 tumors
with EDR to cisplatin had EDR to all 3 drugs. Nineteen
(11%) tumors had EDR or IDR to all 3 chemotherapy drugs
(Figure 2).
EDR or IDR to cisplatin was more prevalent in epithelial
(33%) than nonepithelial tumors (18%) (P¼ .0394). Trends
in the same direction were observed with gemcitabine (35%
vs 25%; P ¼ .1581) and vinorelbine (62% vs 54%;
P ¼ .2875) (Figures 3 and 4). All 4 patients with triple
EDR had epithelial type tumors.
Forty-four (25%; 44/168) patients had chemotherapy be-
fore the specimens were sent for EDR assay. No significant
differences were detected in EDR/IDR versus LDR between
those who received chemotherapy treatment and those who
did not. Those who had prior chemotherapy tended to have
more EDR to cisplatin (odds ratio [OR] ¼ 1.6; P ¼ .2453),
but there were no differences with respect to gemcitabine
(OR ¼ 0.91; P ¼ .8142) and vinorelbine (OR ¼ 1.0;
P ¼ .9797). No significant differences were detected in
EDR/IDR versus LDR between those who were ultimately
resectable and those who were not.
DISCUSSION
Drug resistance profiles for MPM have not been described
in the literature, although the lack of efficacy of most chemo-
therapy is widely acknowledged. Such profiles may contrib-
ute to the individualized treatment of MPM. The 83%
evaluability rate of the MPM cultures in this study is similar
to previous reports for other cancers6,9 and confirms the
feasibility of shipping viable samples of MPM tumors tordiovascular Surgery c Volume 140, Number 2 353
FIGURE 2. Venn diagram: EDR and IDR for mesothlioma specimens.
EDR, Extreme drug resistance; IDR, intermediate drug resistance.
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FIGURE 4. Drug resistance in tumors with nonepithelial histology. Note:
Y-axis is percentage.
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Sa commercial reference laboratory for in vitro analysis. We
were particularly interested in examining specimen growth,
in consideration of the desmoplastic response associated
with MPM, which may interfere with cell growth. A
significant proportion of tumors demonstrated EDR/IDR
(ranging from 27% to 59%) to at least one of the drugs
in the assay panel. Other cancers also have been shown to
exhibit significant levels of drug resistance using this
assay.6,9,10 Approximately 27% of all tumors had EDR
or IDR to cisplatin. Interestingly, tumors with epithelial
histology were more resistant to cisplatin than tumors of
nonepithelial subtype. The finding is counterintuitive,
inasmuch as nonepithelial tumors have worse outcome and,
in addition, any mixed tumor also would contain some
epithelial cells.
In view of the limited chemotherapeutic options available
to treat MPM, new tools for measuring tumor response, in-
cluding in vitro testing, may extend the therapeutic possibil-0
20
40
60
80
100
P
e
r
c
e
n
t
a
g
e
Cisplatin Gemcitabine Vinorelbine
Drug Resistance - Epithelial Histology
Low
Intermediate
Extreme
FIGURE 3. Drug resistance in tumors with epithelial histology. Note:
Y-axis is percentage.
354 The Journal of Thoracic and Cardiovascular Surgities by permitting optimal combination treatments on an
individualized basis. Especially in MPM tumors, where
both the effectiveness of chemotherapy and survival are
low,5,14 tailoring the treatment regimen to optimize efficacy
is of utmost importance. Clearly, this is possible only if
more than one therapy is being contemplated, in which
case a resistance assay might be used as a guide to select
among regimens. Currently, the therapeutic options for
MPM are few in number, and essentially all commonly
used regimens include a platinum compound. However, as
additional agents and combinations are considered, the
ability to simulate a range of combination therapies in vitro
by using the target tumor material may better inform the
therapeutic decision.15
In 2004, the American Society of Clinical Oncology
failed to find a firm basis for integrating chemosensitivity
and resistance assay into the clinical setting.16 Yet recent
publications have shown a positive correlation between
tumor response and a treatment tailored according to chemo-
resistance assays.12,17
Chemosensitivity assays analyze the sensitivity of a tumor
to chemotherapy by measuring the number of tumor cells
that are killed by a particular cancer drug. The test assumes
that a short exposure to the drug, in concentrations at or be-
low clinical peak plasma levels, is representative of tumor
exposure in vivo. This assumption fails to account for the
individual’s biologic reaction to the cytotoxic agent (eg, me-
tabolism or vascular supply) and therefore cannot be extrap-
olated to the in vivo setting. Chemoresistance assays, on the
other hand, expose tumors to chemotherapy agents for lon-
ger periods of time at higher concentrations. Tumor growth
under such conditions in vitro might reasonably be expected
to correlate with in vivo drug resistance.18,19
Indeed, Cortazar and associates14 demonstrated that indi-
vidualized treatment was associated with prolonged survival
for patients with small-cell lung cancer who were random-
ized to receive assay-directed therapy. A significant associa-
tion between in vitro EDR to platinum and clinical outcomes
was also observed in patients with ovarian cancer. Patients
with tumors demonstrating in vitro EDR to platinum were
at significantly increased risk for progression and death
when treated with standard platinum-based regimens.8ery c August 2010
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ter in the EDR assay–guided treatment groups.8,9,12
The limitations of this study are twofold. The EDR assay
used for this study only tested single drugs, whereas
platinum-based combination treatment now is standard for
MPM. Second, we were unable to test pemetrexed (Alimta),
another drug commonly used to treat MPM, because the
EDR assay relies on tritiated thymidine uptake as the end
point for determining tumor resistance, and pemetrexed is
an antifolate that increases thymidine uptake.20 Hence, an al-
ternative assay that does not rely on tritiated thymidine in-
corporation would have to be developed.
Despite these limitations, this study not only establishes
the prevalence of chemotherapy resistance in cultured meso-
thelioma tumors, but also suggests differences in drug resis-
tance based on histopathologic cell type. Our findings
indicate that a significant proportion of MPM tumors have
IDR or EDR to 3 common chemotherapeutic agents.
Clinical implementation of this strategy awaits a prolifera-
tion test applicable to pemetrexed, the availability of addi-
tional chemotherapeutic options, and the integration of
biology and genomic diagnostic tests to accompany the che-
moresistance assay.21 The effectiveness of assay-directed
therapy will need to be addressed in prospective trials.
We acknowledge Dr John Mannick, Ann S. Adams, and William
Francis Powell, Jr, for their valuable contributions to this article.References
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